{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:46:16Z","timestamp":1777099576274,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The costs associated with the treatment of sickle cell disease (SCD) are understudied in low and middle-income countries (LMIC). We evaluated the cost of treating SCD-related acute complications and the potential cost-savings of hydroxyurea in a specialized hematology center in Brazil.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The costs (US dollars) of emergency department (ED) and hospitalizations from SCD-related complications between 01.01.2018 and 06.30.2018 were ascertained using absorption and micro-costing approaches. The reasons for acute hospital visits were grouped as: 1) vaso-occlusive (VOC) pain, 2) infection, 3) anemia exacerbation, and 4) chronic organ damage complications. Hydroxyurea adherence was estimated by medication possession ratio (MPR) during the study period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 1144 patients, median age 17\u2009years (range 0\u201370), 903 (78.9%) with HbSS\/HbS\u03b2<jats:sup>0<\/jats:sup>-thalassemia, 441 (38.5%) prescribed hydroxyurea, visited the ED, of whom 381 (33%) were admitted. VOC accounted for 64% of all ED visits and 60% of all admissions. Anemia exacerbation was the most expensive reason for ED visit ($321.87\/visit), while chronic organ damage carried the highest admission cost ($2176.40\/visit). Compared with other genotypes, individuals with HbSS\/HbS\u03b2<jats:sup>0<\/jats:sup>-thalassemia were admitted more often (79% versus 21%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), and their admission costs were higher ($1677.18 versus $1224.47\/visit, <jats:italic>p<\/jats:italic>\u2009=\u20090.0001). Antibiotics and analgesics accounted for 43% and 42% of the total ED costs, respectively, while housing accounted for 46% of the total admission costs. Costs of ED visits not resulting in admissions were lower among HbSS\/HbS\u03b2<jats:sup>0<\/jats:sup>-thalassemia individuals with hydroxyurea MPR \u226565% compared with visits by patients with MPR\u2009&lt;65% ($98.16\/visit versus $182.46\/visit, <jats:italic>p<\/jats:italic>\u2009=\u20090.0007). No difference in admission costs were observed relative to hydroxyurea use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>In a LMIC hematology-specialized center, VOCs accounted for most acute visits from patients with SCD, but costs were highest due to anemia exacerbation. Analgesics, antibiotics, and housing drove most expenses. Hydroxyurea may reduce ED costs among individuals with HbSS\/HbS\u03b2<jats:sup>0<\/jats:sup>-thalassemia but is dependent on adherence level.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-021-07461-6","type":"journal-article","created":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T16:02:42Z","timestamp":1641657762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country"],"prefix":"10.1186","volume":"22","author":[{"given":"Clarisse","family":"Lobo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delaine","family":"Fidlarczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Duran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thais","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia Matos","family":"do Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nickhill","family":"Bhakta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane S.","family":"Hankins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,8]]},"reference":[{"key":"7461_CR1","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","volume":"4","author":"GJ Kato","year":"2018","unstructured":"Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.","journal-title":"Nat Rev Dis Primers"},{"issue":"4 Suppl","key":"7461_CR2","doi-asserted-by":"publisher","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","volume":"38","author":"KL Hassell","year":"2010","unstructured":"Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512\u201321.","journal-title":"Am J Prev Med"},{"issue":"1","key":"7461_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/pbc.24711","volume":"61","author":"CL Lobo","year":"2014","unstructured":"Lobo CL, Ballas SK, Domingos AC, Moura PG, do Nascimento EM, Cardoso GP, et al. Newborn screening program for hemoglobinopathies in Rio de Janeiro, Brazil. Pediatr Blood Cancer. 2014;61(1):34\u20139.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"7461_CR4","first-page":"279","volume":"86","author":"AP Fernandes","year":"2010","unstructured":"Fernandes AP, Januario JN, Cangussu CB, Macedo DL, Viana MB. Mortality of children with sickle cell disease: a population study. J Pediatr. 2010;86(4):279\u201384.","journal-title":"J Pediatr"},{"key":"7461_CR5","doi-asserted-by":"crossref","unstructured":"Santo AH. Sickle cell disease related mortality in Brazil, 2000-2018. Hematol Transfus Cell Ther.\u00a02020;S2531-1379(20)31299-2.","DOI":"10.1016\/j.htct.2020.09.154"},{"key":"7461_CR6","doi-asserted-by":"publisher","unstructured":"Paulukonis ST, Feuchtbaum LB, Coates TD, Neumayr LD, Treadwell MJ, Vichinsky EP, Hulihan MM. Emergency department utilization by Californians with sickle cell disease 2005\u20132014. Pediatr Blood Cancer. 2017;64:e26390. https:\/\/doi.org\/10.1002\/pbc.26390.","DOI":"10.1002\/pbc.26390"},{"issue":"1","key":"7461_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.36469\/jheor.2020.12852","volume":"7","author":"N Shah","year":"2020","unstructured":"Shah N, Bhor M, Xie L, Paulose J, Yuce H. Medical resource use and costs of treating sickle cell-related Vaso-occlusive crisis episodes: a retrospective claims study. J Health Econ Outcomes Res. 2020;7(1):52\u201360.","journal-title":"J Health Econ Outcomes Res"},{"issue":"11","key":"7461_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1080\/13696998.2020.1813144","volume":"23","author":"NR Shah","year":"2020","unstructured":"Shah NR, Bhor M, Latremouille-Viau D, Kumar Sharma V, Puckrein GA, Gagnon-Sanschagrin P, et al. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers. J Med Econ. 2020;23(11):1345\u201355.","journal-title":"J Med Econ"},{"issue":"9","key":"7461_CR9","doi-asserted-by":"publisher","first-page":"e28588","DOI":"10.1002\/pbc.28588","volume":"67","author":"FW Thielen","year":"2020","unstructured":"Thielen FW, Houwing ME, Cnossen MH, Al Hadithy-Irgiztseva IA, Hazelzet JA, Groot CAU, et al. Cost of health care for paediatric patients with sickle cell disease: an analysis of resource use and costs in a European country. Pediatr Blood Cancer. 2020;67(9):e28588.","journal-title":"Pediatr Blood Cancer"},{"issue":"7 Suppl 1","key":"7461_CR10","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1097\/MLR.0b013e31819bc064","volume":"47","author":"KD Frick","year":"2009","unstructured":"Frick KD. Microcosting quantity data collection methods. Med Care. 2009;47(7 Suppl 1):S76\u201381.","journal-title":"Med Care"},{"key":"7461_CR11","volume-title":"Gest\u00e3o de custos para hospitais: conceitos, metodologias e aplica\u00e7\u00f5es: Atlas","author":"JA Falk","year":"2001","unstructured":"Falk JA. Gest\u00e3o de custos para hospitais: conceitos, metodologias e aplica\u00e7\u00f5es: Atlas; 2001."},{"issue":"6","key":"7461_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/ajh.21408","volume":"84","author":"TL Kauf","year":"2009","unstructured":"Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84(6):323\u20137.","journal-title":"Am J Hematol"},{"issue":"2","key":"7461_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/pds.1698","volume":"18","author":"NM Vink","year":"2009","unstructured":"Vink NM, Klungel OH, Stolk RP, Denig P. Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf. 2009;18(2):159\u201365.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"7461_CR14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1198\/106186006X133933","volume":"15","author":"T Hothorn","year":"2006","unstructured":"Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat. 2006;15(3):651\u201374.","journal-title":"J Comput Graph Stat"},{"key":"7461_CR15","unstructured":"JA CRJ. Sickle cell disease in Brazil. Revista Brasileira de Hematologia e Hemoterapia. 2007;29(3)."},{"issue":"2","key":"7461_CR16","doi-asserted-by":"publisher","first-page":"e0246700","DOI":"10.1371\/journal.pone.0246700","volume":"16","author":"J Gyamfi","year":"2021","unstructured":"Gyamfi J, Ojo T, Epou S, Diawara A, Dike L, Adenikinju D, et al. Evidence-based interventions implemented in low-and middle-income countries for sickle cell disease management: a systematic review of randomized controlled trials. Plos One. 2021;16(2):e0246700.","journal-title":"Plos One"},{"issue":"4 Suppl","key":"7461_CR17","doi-asserted-by":"publisher","first-page":"S550","DOI":"10.1016\/j.amepre.2010.01.004","volume":"38","author":"DD Amendah","year":"2010","unstructured":"Amendah DD, Mvundura M, Kavanagh PL, Sprinz PG, Grosse SD. Sickle cell disease-related pediatric medical expenditures in the U.S. Am J Prev Med. 2010;38(4 Suppl):S550\u20136.","journal-title":"Am J Prev Med"},{"issue":"9","key":"7461_CR18","first-page":"1121","volume":"26","author":"A Campbell","year":"2020","unstructured":"Campbell A, Cong Z, Agodoa I, Song X, Martinez DJ, Black D, et al. The economic burden of end-organ damage among Medicaid patients with sickle cell disease in the United States: a population-based longitudinal claims study. J Manag Care Spec Pharm. 2020;26(9):1121\u20139.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"7461_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12955-019-1225-7","volume":"17","author":"N Shah","year":"2019","unstructured":"Shah N, Bhor M, Xie L, Halloway R, Arcona S, Paulose J, et al. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study. Health Qual Life Outcomes. 2019;17(1):155.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"7461_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1542\/peds.2013-0333","volume":"132","author":"WC Wang","year":"2013","unstructured":"Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics. 2013;132(4):677\u201383.","journal-title":"Pediatrics"},{"issue":"5","key":"7461_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","volume":"376","author":"KI Ataga","year":"2017","unstructured":"Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429\u201339.","journal-title":"N Engl J Med"},{"issue":"2","key":"7461_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<117::AID-AJH5>3.0.CO;2-V","volume":"58","author":"Y Niihara","year":"1998","unstructured":"Niihara Y, Zerez CR, Akiyama DS, Tanaka KR. Oral L-glutamine therapy for sickle cell anemia: I. subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol. 1998;58(2):117\u201321.","journal-title":"Am J Hematol"},{"issue":"6","key":"7461_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1903212","volume":"381","author":"E Vichinsky","year":"2019","unstructured":"Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, et al. A phase 3 randomized trial of Voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509\u201319.","journal-title":"N Engl J Med"},{"issue":"3","key":"7461_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/pubmed\/fdu026","volume":"37","author":"E Pizzo","year":"2015","unstructured":"Pizzo E, Laverty AA, Phekoo KJ, AlJuburi G, Green SA, Bell D, et al. A retrospective analysis of the cost of hospitalizations for sickle cell disease with crisis in England, 2010\/11. J Public Health (Oxf). 2015;37(3):529\u201339.","journal-title":"J Public Health (Oxf)."},{"issue":"4","key":"7461_CR25","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/pubmed\/fds035","volume":"34","author":"G Aljuburi","year":"2012","unstructured":"Aljuburi G, Laverty AA, Green SA, Phekoo KJ, Banarsee R, Okoye NV, et al. Trends in hospital admissions for sickle cell disease in England, 2001\/02-2009\/10. J Public Health (Oxf). 2012;34(4):570\u20136.","journal-title":"J Public Health (Oxf)"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-07461-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-021-07461-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-07461-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T16:04:42Z","timestamp":1641657882000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-021-07461-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,8]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7461"],"URL":"https:\/\/doi.org\/10.1186\/s12913-021-07461-6","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,8]]},"assertion":[{"value":"12 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective de-identified study was approved by the HEMORIO Ethics Committee as secondary use of already existing data with a waiver of consent from participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Clarisse Lobo received funds from the Pfizer Healthcare Foundation to conduct this work. Jane S. Hankins receives consulting fees from Forma Therapeutics, Global Blood Therapeutics, and bluebird bio. Remaining authors do not have any competing interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}